



CITURGIA BIOCHEMICALS LIMITED

Regd. Office: 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,
Bhayandar East, Thane-401105, Maharashtra. **CIN:** L24100MH1974PLC017773
Phone: - 91 9650923555, **Website:** www.citurgiabio.com; **E-mail id:** citurgia_bio@yahoo.com

Date: 13.02.2019

To,

BSE Limited
P J Towers, Dalal Street
Mumbai - 400001
Scrip Code: 506373,
Scrip ID: CITURGIA

Sub: Outcome of the Board Meeting and submission of Unaudited Financial Results for Quarter ended 31st December, 2018.


Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the Company held today on 13th February, 2019, the following decisions were taken:

1. The Board considered and approved the Unaudited Financial Results for the Quarter ended 31st December, 2018.
2. Limited Review Report issued by the statutory auditor for the quarter ended 31st December, 2018.

We request you to kindly take the above information on record.

For CITURGIA BIOCHEMICALSLIMITED


AKSHOD KUMAR SHARMA
WHOLE TIME DIRECTOR
DIN: 02112607



CITURGIA BIOCHEMICALS LIMITED

Regd Office: 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,

Bhayandar East, Thane-401105, Maharashtra CIN: L24100MH1974PLC017773

Phone: - 91 9650923555, Website: www.citurgiabio.com; E-mail id: citurgia_bio@yahoo.com

(Amount in
Lacs)

PART-I STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST, DECEMBER 2018						
Particulars	Quarter Ended			Period Ended		Year Ended
	3 Months ended 31/12/2018	Preceding 3 months ended 30/09/2018	Corresponding 3 months ended 31/12/2017	Year to Figure for current year ended 31.12.2018	Year to Figure for previous year ended 31.12.2017	Current Ended 31/03/2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Total Income from Operations	-	-	-	-	-
II.	Other Income	-	-	-	-	-
III.	Total Revenue (I+II)	-	-	-	-	-
IV.	Expenses					
	a) Cost of Materials consumed	-	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, WIP and stock in trade	-	-	-	-	-
	d) Employee benefits expenses	3.19	8.02	0.24	10.03	3.88
	e) Depreciation and amortization expenses	8.02	16.04	9.30	24.07	37.21
	f) Other expenses	2.55	6.13	7.31	9.87	14.36
	Total Expenses	13.76	30.20	16.86	43.96	55.45
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-V)	(13.76)	(30.20)	(16.86)	(43.96)	(55.45)
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (VI-VII)	(13.76)	(30.20)	(16.86)	(43.96)	(55.45)
VIII	Extraordinary items	-	-	-	-	-
IX	Profit/(Loss) before tax (VIII-IX)	(13.76)	(30.20)	(16.86)	(43.96)	(55.45)
X	Tax expenses					
	a) Current Tax	-	-	-	-	-
	a) Income Tax Adjustment	-	-	-	-	-
	a) MAT Credit Entitlement	-	-	-	-	-
	b) Deferred Tax Liabilities / (Assets)	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(13.76)	(30.20)	(16.86)	(43.96)	(55.45)
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(13.76)	(30.20)	(16.86)	(43.96)	(55.45)
XVI	Other Comprehensive Income					

	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(13.76)	(30.20)	(16.86)	(43.96)	(40.19)	(55.45)
XVIII	Earnings per equity share (for continuing operation):						
	(1) Basic	0.001	0.002	0.000	0.003	0.002	0.005
	(2) Diluted	0.001	0.002	0.000	0.003	0.002	0.005
XIX	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XX	Earning Per Share (for discontinued & continuing operations)						
	a) Basic	0.001	0.002	0.000	0.003	0.002	0.005
	b) Diluted	0.001	0.002	0.000	0.003	0.002	0.005

Notes:

- | | |
|----------|---|
| 1 | The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13/02/2019. The Statutory auditors have carried out Limited Review Report for the same. |
| 2 | The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications. |
| 3 | Company has made business only in one segment during the period hence no segment reporting is required. |

Date: 13.02.2019

Place: Mumbai

For CITURGIA BIOCHEMICALSLIMITED

G.K. Sharma
AKSHOD KUMAR SHARMA
WHOLE TIME DIRECTOR
DIN: 02112607




CITURGIA BIOCHEMICALS LIMITED

Regd. Office: 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,
Bhayandar East, Thane-401105, Maharashtra. **CIN:** L24100MH1974PLC017773
Phone: - 91 9650923555, **Website:** www.citurgiabio.com; **E-mail id:** citurgia_bio@yahoo.com

Reconciliation of Net Profit after tax as per previously reported under Indian Accounting Standard and Ind AS for the quarter ended December 31, 2018

S No.	Particulars	Amount (Rs. In lacs)
1	Net Profit / loss for the Period under Previous Indian AS	(13.76)
2	Adjustment	
	- Impact of net adjustments on income	0
	- Other Misc Adjustment	0
3	Net Profit for the period under Ind AS	(13.76)

For CITURGIA BIOCHEMICALSLIMITED


AKSHOD KUMAR SHARMA
WHOLE TIME DIRECTOR
DIN: 02112607



G.P. KESHRI & ASSOCIATES

Chartered Accountants

Head Office: A-215/5, Chawla Complex, Vikas Marg, Shakarpur, New Delhi-110092 (Delhi)
Phone: +91 011 22546181, Mobile: +91 9818433797, +91 8882710429, Fax: +91 011 22546181
E-Mail: gopalkeshri@yahoo.com

LIMITED REVIEW REPORT

To,
Board of Directors of
M/S Citurgia Biochemicals Limited

We have reviewed the accompanying statement of Unaudited Financial Results of M/S Citurgia Biochemicals Limited (the "Company"), for the quarter and period ended 31st December 2018, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Companies Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued hereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosed Requirements) Regulations, 2015 and SEBI circular dated 5th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. P. Keshri & Associates.
Chartered Accountants

CA. Gopal Prasad Keshri
Partner
FRN: 017251N
M.NO: 098476



Place: New Delhi
Date: 13/02/2019